

30 July 2021

Diaceutics PLC
("Diaceutics" or "the Company")

PDMR Shareholding/Share Incentive Plan

[Diaceutics PLC](#), (AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified that on 29 July 2021 Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust ("EBT"), have purchased ordinary shares ("Shares") on behalf of Susanne Munksted and Damian Thornton (both PDMRs), in respect of their purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.

It was announced on 30 April 2021 that under the SIP Scheme, the Company will match purchases with a matched share award over an equivalent number of Shares purchased by the employee, over the period to April 2022 and subsequent 12 month periods thereafter, in the proportion of 2:1 for all purchases up to and including April 2022 and 1:1 for all purchases thereafter. For participants in the Global SIP Scheme these matched awards are provided by a single one-off option or conditional share award.

A one-off option or conditional award in respect of purchases by each PDMR up to and including 30 April 2022 has been granted by the Company today as follows:

Name	Number of Share Options granted	Type of Matched Award	Normal Vesting Date
Susanne Munksted (MD and PDMR)	Such number of Shares as is equal to two times the number of Shares purchased up to and including 30 April 2022	Conditional share award	30 July 2024
Damian Thornton (COO and PDMR)		Nil cost option	28 May 2024

Enquiries:

Diaceutics PLC

Philip White, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison
Stewart Wallace
Nick Adams

Alma PR

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

Caroline Forde
Robyn Fisher
Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Susanne Munksted

2 Reason for notification										
a.	Position/Status	Managing Director and PDMR								
b.	Initial notification/ Amendment	Initial								
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a.	Name	Diaceutics PLC								
b.	LEI	213800VEWQBB39ZB8J81								
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted										
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64								
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")								
c.	Price(s) and volume(s)	<p>Share purchase:</p> <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>112.00 p</td> <td>127</td> </tr> </tbody> </table> <p>Conditional share award:</p> <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>Two times the number of Shares purchased up to and including 30 April 2022, with a conditional award of 254 shares pursuant to shares purchased in July</td> </tr> </tbody> </table>	Price(s)	Volume(s)	112.00 p	127	Price(s)	Volume(s)	Nil	Two times the number of Shares purchased up to and including 30 April 2022, with a conditional award of 254 shares pursuant to shares purchased in July
Price(s)	Volume(s)									
112.00 p	127									
Price(s)	Volume(s)									
Nil	Two times the number of Shares purchased up to and including 30 April 2022, with a conditional award of 254 shares pursuant to shares purchased in July									
e.	Date of the transaction	Share purchase: 29 July 2021 Conditional share award Option award: 30 July 2021								
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market								

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Damian Thornton
2 Reason for notification		
a.	Position/Status	Chief Operating Officer and PDMR
b.	Initial notification/ Amendment	Initial

	Amendment											
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor											
a.	Name	Diaceutics PLC										
b.	LEI	213800VEWQBB39ZB8J81										
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted											
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64										
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares to matched by the grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP")										
c.	Price(s) and volume(s)	<p>Share purchase:</p> <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>112.00 p</td> <td>132</td> </tr> <tr> <td colspan="2">Options:</td> </tr> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> <tr> <td>Nil</td> <td>Two times the number of Shares purchased up to and including 30 April 2022, with 264 nil cost options granted pursuant to shares purchased in July</td> </tr> </tbody> </table>	Price(s)	Volume(s)	112.00 p	132	Options:		Price(s)	Volume(s)	Nil	Two times the number of Shares purchased up to and including 30 April 2022, with 264 nil cost options granted pursuant to shares purchased in July
Price(s)	Volume(s)											
112.00 p	132											
Options:												
Price(s)	Volume(s)											
Nil	Two times the number of Shares purchased up to and including 30 April 2022, with 264 nil cost options granted pursuant to shares purchased in July											
e.	Date of the transaction	Share purchase: 29 July 2021 Option award: 30 July 2021										
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Option award: Off-Market										

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHDKKBPPBKDNON